In my role as Vice President and Franchise Head, R&D, 我在澳门在线赌城娱乐领导fama -trastuzumab deruxtecan-nxki项目，负责该化合物的综合开发和商业战略. 这个令人兴奋的项目正在与澳门第一赌城在线娱乐的合作伙伴合作开发，以满足HER-2驱动肿瘤患者的需求, Daiichi Sankyo, 它将成为目前肿瘤学领域最大、最令人兴奋的发展项目之一.

A medical oncologist by training, 我有丰富的药物开发经验，从早期试验到全球申请, as well as strong management and leadership experience. At AstraZeneca, 我曾领导开发项目，探索多种肿瘤类型的化合物，包括乳腺癌, lung cancer, ovarian cancer and prostate cancer.

Throughout my career, I have focused on building strong, collaborative, 在多元化的团队中，每个团队成员都感到受到重视，并能在解决癌症的问题上发挥最大的作用. 我是多元化和包容性的倡导者，并领导澳门在线赌城娱乐肿瘤学全球包容性和多样性委员会. I am also passionate about STEM (science, technology, 他曾在美国科学与工程节上发表演讲, X-STEM Congress and USA Science and Engineering Festival.

Before joining AstraZeneca, 我曾担任Genentech的集团医疗总监，负责领导cobimetinib的临床开发, a MEK inhibitor being explored in melanoma, 同时也是妇科恶性肿瘤中所有贝伐单抗研究的临床领导者.   

我是一名作者，并推动了许多项目，导致了许多同行评审的出版物 Lancet Oncology and New England Journal of Medicine. 我也是包括美国临床肿瘤学会在内的各种专业肿瘤医学学会的成员, 美国癌症研究协会和欧洲肿瘤医学学会.

在波士顿大学医学院获得病理学和免疫学医学学位后, 我在纪念斯隆·凯特琳癌症中心完成了肿瘤学研究.

 

只有在最终改善患者生活的决策过程中引入多样化的思想，澳门第一赌城在线娱乐才能实现消灭癌症的宏伟目标.

Mika Sovak Vice President and Franchise Head, R&D, AstraZeneca

CURRENT ROLE

Vice President and Franchise Head, R&D, AstraZeneca (fam‐trastuzumab deruxtecan)

2017 - 2019

曾担任澳门在线赌城娱乐(AstraZeneca)的免疫肿瘤学肺癌组合副总裁

2015 - 2017

在澳门在线赌城娱乐担任执行董事，负责奥拉帕尼项目在多种疾病中的全球临床开发

2012 - 2015

Genentech副集团医疗总监，负责领导cobimetinib (MEK抑制剂)的临床开发

Featured publications

接受奥拉帕尼维持单药治疗的铂敏感复发性浆液性卵巢癌患者的总生存率:来自一项随机研究的最新分析, placebo-controlled, double-blind phase 2 trial

Lederman JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U. Lancet Oncology. 2016. 17(11): 1579

http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30376-X/fulltext

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, Mandala M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Sovak MA, Chang I, Choong N, Hack SP, McArthur GA, Ribas A. N Engl J. Med. 2014. 371(20):1867

http://www.nejm.org/doi/full/10.1056/nejmoa1408868

 

妇科肿瘤组研究0218的独立放射学审查, 贝伐单抗用于晚期上皮性卵巢的主要治疗的III期试验, primary peritoneal, or fallopian tube cancer

Burger RA, Brady MF, Rhee J, Sovak MA, Kong G, Nguyen HP, Bookman MA. Gynecol Oncol. 2013. 131(1):21-6

http://www.gynecologiconcology-online.net/article/S0090-8258(13)01020-2/abstract

万德替尼联合化疗诱导后万德替尼或安慰剂作为晚期非小细胞肺癌患者的维持:一项随机II期PrECOG研究(PrE0501)

Aisner J, Manola JB, Dakhil SR, Stella PJ, Sovak MA, Schiller JH. J Thorac Oncol. 2013. 8(8):1075-83

http://www.jto.org/article/S1556-0864(15)33448-1/fulltext

 

一项随机双盲安慰剂对照III期试验，化疗加或不加贝伐单抗治疗铂敏感复发性上皮性卵巢患者, Primary Peritoneal, or Fallopian Tube Cancer

Aghajanian C, Blank SV, Goff B, Judson P, Teneriello MG, Husain A, Sovak MA, Ying J, Nycum L. Journal of Clinical Oncology. 2012. 30(17):2039-45

http://ascopubs.org/doi/abs/10.1200/jco.2011.29.18_suppl.lba5007

 

A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors

Simon GR, Ilaria RL Jr, Sovak MA, Williams CC, Haura EB, Cleverly AL, Sykes AK, Wagner MM, de Alwis DP, Slapak CA, Miller MA, Spriggs DR. Cancer Chemother Pharmacol. 2011. Nov;68(5):1233-41

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3215883/

 

 

合理设计MAPK通路激活实体瘤的治疗方法:紫杉醇和硼替佐米的I期研究，采用适应性剂量发现方法

Mehnert JM, Tan AR, Moss R, Poplin E, Stein MN, Sovak M， Levinson K, Lin H, Kane M, Gounder M, Lin Y, shiwj, White E, Rubin EH, Karantza V. Mol Cancer Ther. 2011. Aug;10(8):1509-19

http://mct.aacrjournals.org/content/10/8/1509.long

 

紫杉醇和卡铂治疗晚期或复发子宫内膜癌:一项大型回顾性研究

Sovak MA, Dupont J, Hensley ML, Ishill N, Gerst S, Abu-Rustum N, Anderson S, Barakat R, Konner J, Poyner E, Sabbatini P, Spriggs DR, Aghajanian C. Int J Gyn Onc. 2007. 17:197-203

http://ascopubs.org/doi/abs/10.1200/jco.2005.23.16_suppl.5020

 

Rational drug sequencing of paclitaxel, gemcitabine, IV期和部分IIIB期非小细胞肺癌患者使用卡铂

Sovak MA, Lutzker S, Zheng L, Guensch L, Joyce M, Wu Y, Aisner J. Lung Cancer. 2006. 53:177-81

http://www.lungcancerjournal.info/article/S0169-5002(06)00273-X/abstract

 

紫杉醇和卡铂辅助治疗高危III期和IV期子宫内膜癌的回顾性研究

Sovak MA, Hensley ML, Dupont J, Ishill N, Alektiar KM, Abu-Rustum N, Barakat R, Chi DS, Sabbatini P, Spriggs DR, Aghajanian C. Gynecol Oncol. 2006. 103:451-7

http://www.gynecologiconcology-online.net/article/S0090-8258(06)00247-2/abstract